Home / Health / Kids Obesity Drug Shows Remarkable Results in Trial
Kids Obesity Drug Shows Remarkable Results in Trial
7 Sep
Summary
- Semaglutide treated 40.4% of children aged 6-12, resolving obesity.
- Patients received diet and exercise support alongside medication.
- Drug's safety profile aligns with adult and adolescent trial data.
In a significant development for pediatric weight management, Novo Nordisk announced promising results from its STEP Young clinical trial. The study, conducted on children aged 6 to under 12, investigated the efficacy of semaglutide, the key component in the widely recognized weight-loss medication Wegovy.
The trial revealed that approximately 40.4% of young participants who received once-weekly subcutaneous semaglutide achieved a state where they were no longer classified as having obesity. This positive outcome was observed after 68 weeks of adherence to the treatment regimen.
Crucially, all children in the study benefited from comprehensive lifestyle modification support. This included adherence to a reduced-calorie diet and increased participation in physical activities throughout the trial period.
Novo Nordisk's Chief Scientific Officer, Martin Holst Lange, expressed optimism about these findings, highlighting semaglutide's potential as a medical treatment for children living with obesity. The trial successfully met its primary objective, demonstrating a superior reduction in body mass index for the semaglutide group compared to the placebo group.
The safety and tolerability profile of semaglutide in this younger demographic proved consistent with observations made during trials involving adults and adolescents. This suggests a predictable safety landscape as the drug's application is explored in pediatric populations.
